"The Readout LOUD" podcast discusses the challenges of launching essential treatments for sickle cell disease. Manufacturing problems have slowed the market launch of this treatment. The weekly program also covers the financial outlook of Novo Nordisk and Eli Lilly. The latest outlook focuses on GLP-1 drugs. These drugs are the subject of a closer look in relation to their development and potential. The discussion highlights current barriers to the availability of key therapies.